EPIC-Norfolk Publications Database

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, and Kastelein JJ

Journal of the American College of Cardiology. Jul 2007

(DOI : 10.1016/j.jacc.2007.09.060)

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.

van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, and Khaw KT

Annals of internal medicine. May 2007

(DOI : 10.7326/0003-4819-146-9-200705010-00007)

Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

El Harchaoui K, van der Steeg WA, Stroes ES, Kuivenhoven JA, Otvos JD, Wareham NJ, Hutten BA, Kastelein JJ, Khaw KT, and Boekholdt SM

Journal of the American College of Cardiology. Aug 2006

(DOI : 10.1016/j.jacc.2006.09.043)

Role of CETP inhibitors in the treatment of dyslipidemia.

van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, and Kastelein JJ

Current opinion in lipidology. Nov 2004

(DOI : 10.1097/00041433-200412000-00002)